Coverage / NVO / Trade Card

NVO

Novo Nordisk A/S

OPPORTUNISTIC BUY 2026-10-04 Data 8 days old USD 37.32 Healthcare - Drug Manufacturers - GeneralAWAIT ENTRY
ACTIONABLEMethodology gates passed
55

Position levels

Currenttoday
USD 37.32
Buy <=wait / entry
USD 30.00
Trim >=take some off
USD 38.00
Thesis breakA confirmed 2027 profit warning alongside material US policy action tightening m...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case23%100 / 10023.0
Base case47%62 / 10029.1
Bear case30%10 / 1003.0
Weighted conviction55 / 100 - OPPORTUNISTIC BUY

Top risks

  • Akero Therapeutics acquisition ($4.7bn cash + $0.5bn CVR)
  • Vivtex partnership (up to $2.1bn deal for oral obesity drugs) and Veru agreement
  • 2026 guidance: adjusted sales and operating profit down 6% to flat, with explicit US sales decline
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.